Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Biocryst Pharmaceuticals (BCRX) Change in Accured Expenses (2023)

Biocryst Pharmaceuticals' Change in Accured Expenses history spans 7 years, with the latest figure at $1.6 million for Q3 2023.

For Q3 2023, Change in Accured Expenses changed N/A year-over-year to $1.6 million; the TTM value through Sep 2023 reached $1.2 million, changed N/A, while the annual FY2021 figure was $4.2 million, 38.4% down from the prior year.
Change in Accured Expenses reached $1.6 million in Q3 2023 per BCRX's latest filing, up from -$2.8 million in the prior quarter.
In the past five years, Change in Accured Expenses ranged from a high of $1.6 million in Q3 2023 to a low of $1.6 million in Q3 2023.